Mozobil(plerixafor)
Mozobil, Plerixafor (plerixafor) is a small molecule pharmaceutical. Plerixafor was first approved as Mozobil on 2008-12-15. It is used to treat multiple myeloma and non-hodgkin lymphoma in the USA. It has been approved in Europe to treat hematopoietic stem cell transplantation, lymphoma, and multiple myeloma. The pharmaceutical is active against C-X-C chemokine receptor type 4. In addition, it is known to target atypical chemokine receptor 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Mozobil, Plerixafor (discontinued: Plerixafor)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mozobil | New Drug Application | 2025-09-22 |
| plerixafor | ANDA | 2024-12-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| non-hodgkin lymphoma | — | D008228 | C85.9 |
| multiple myeloma | — | D009101 | C90.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2562 | Injection, plerixafor, 1 mg |
Clinical
Clinical Trials
184 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 6 | 24 | 3 | 1 | 5 | 36 |
| Lymphoma | D008223 | — | C85.9 | 4 | 12 | 2 | 1 | 7 | 25 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 2 | 4 | — | 1 | 1 | 8 |
| Autologous transplantation | D014182 | — | — | — | 1 | — | 1 | 3 | 5 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 7 | 31 | 4 | — | 13 | 53 |
| Leukemia | D007938 | — | C95 | 20 | 15 | 1 | — | 2 | 29 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 18 | 16 | 1 | — | 2 | 27 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 9 | 2 | — | 9 | 22 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 13 | 10 | 1 | — | — | 17 |
| Hodgkin disease | D006689 | — | C81 | 3 | 12 | 1 | — | 2 | 16 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 6 | 8 | 1 | — | 2 | 15 |
| Neutropenia | D009503 | — | D70 | 2 | 2 | 1 | — | — | 3 |
| Transplantation | D014180 | — | — | 1 | 1 | 1 | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | 1 | — | — | 2 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia | D007951 | — | C92 | 14 | 11 | — | — | — | 18 |
| Myelodysplastic syndromes | D009190 | — | D46 | 8 | 9 | — | — | 2 | 15 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 5 | 4 | — | — | 2 | 10 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 4 | 6 | — | — | 1 | 9 |
| Neoplasms | D009369 | — | C80 | 4 | 2 | — | — | 1 | 7 |
| Hematologic neoplasms | D019337 | — | — | 3 | 4 | — | — | — | 5 |
| Syndrome | D013577 | — | — | 3 | 4 | — | — | — | 5 |
| Fanconi anemia | D005199 | Orphanet_84 | D61.03 | 4 | 4 | — | — | — | 5 |
| Healthy volunteers/patients | — | — | — | 3 | 2 | — | — | — | 5 |
| Glioblastoma | D005909 | EFO_0000515 | — | 3 | 3 | — | — | — | 4 |
Show 60 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | — | — | — | 2 | 3 |
| Hairy cell leukemia | D007943 | — | C91.4 | 1 | — | — | — | 2 | 3 |
| Burkitt lymphoma | D002051 | — | C83.7 | 1 | — | — | — | 2 | 3 |
| Large-cell lymphoma immunoblastic | D016400 | — | — | 1 | — | — | — | 2 | 3 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | 2 | 3 |
| Waldenstrom macroglobulinemia | D008258 | — | C88.0 | 1 | — | — | — | 1 | 2 |
| Lymphomatoid granulomatosis | D008230 | — | C83.8 | 1 | — | — | — | 1 | 2 |
| Adenocarcinoma | D000230 | — | — | 2 | — | — | — | — | 2 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | 1 | — | — | — | — | 1 |
Show 17 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sezary syndrome | D012751 | — | C84.1 | — | — | — | — | 2 | 2 |
| Mycosis fungoides | D009182 | — | C84.0 | — | — | — | — | 2 | 2 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | — | — | — | — | 2 | 2 |
| Myeloid leukemia chronic-phase | D015466 | — | — | — | — | — | — | 2 | 2 |
| Mycoses | D009181 | — | B35-B49 | — | — | — | — | 1 | 1 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | — | — | — | — | 1 | 1 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | — | — | — | — | 1 | 1 |
| Immunoblastic lymphadenopathy | D007119 | EFO_1001350 | C86.5 | — | — | — | — | 1 | 1 |
| Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | — | — | — | — | 1 | 1 |
| Plasmablastic lymphoma | D000069293 | — | C83.3 | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Plerixafor |
| INN | plerixafor |
| Description | Plerixafor is an azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. It has a role as an immunological adjuvant, an antineoplastic agent, an anti-HIV agent and a C-X-C chemokine receptor type 4 antagonist. It is an azamacrocycle, a crown amine, a secondary amino compound, an azacycloalkane, a tertiary amino compound and a member of benzenes. It is functionally related to a 1,4,8,11-tetraazacyclotetradecane. |
| Classification | Small molecule |
| Drug class | CXCR receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1 |
Identifiers
| PDB | — |
| CAS-ID | 110078-46-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL18442 |
| ChEBI ID | — |
| PubChem CID | 65015 |
| DrugBank | DB06809 |
| UNII ID | S915P5499N (ChemIDplus, GSRS) |
Target
Agency Approved
CXCR4
CXCR4
Organism
Homo sapiens
Gene name
CXCR4
Gene synonyms
NCBI Gene ID
Protein name
C-X-C chemokine receptor type 4
Protein synonyms
CD184, CD184 antigen, chemokine (C-X-C motif) receptor 4, FB22, Fusin, HM89, LAP-3, LCR1, LESTR, Leukocyte-derived seven transmembrane domain receptor, Lipopolysaccharide-associated protein 3, LPS-associated protein 3, neuropeptide Y receptor Y3, neuropeptide Y3 receptor, NPYRL, SDF-1 receptor, seven transmembrane helix receptor, seven-transmembrane-segment receptor, spleen, Stromal cell-derived factor 1 receptor
Uniprot ID
Mouse ortholog
Cxcr4 (12767)
C-X-C chemokine receptor type 4 (Q4KMW1)
Alternate
ACKR3
ACKR3
Organism
Homo sapiens
Gene name
ACKR3
Gene synonyms
CMKOR1, CXCR7, GPR159, RDC1
NCBI Gene ID
Protein name
atypical chemokine receptor 3
Protein synonyms
C-X-C chemokine receptor type 7, chemokine (C-X-C motif) receptor 7, Chemokine orphan receptor 1, CXC-R7, CXCR-7, G protein-coupled receptor, G-protein coupled receptor 159, G-protein coupled receptor RDC1 homolog, RDC-1
Uniprot ID
Mouse ortholog
Ackr3 (12778)
atypical chemokine receptor 3 (Q91WI0)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,347 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,021 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use